Profil
Ian Jacobson is currently the Chief Executive Officer at Cpoint Capital, Inc. and a Director at Juno Pharmaceuticals Corp.
He previously worked as a Non-Executive Director at Litha Healthcare Group Ltd.
Postes actifs de Ian Jacobson
| Sociétés | Poste | Début |
|---|---|---|
| Cpoint Capital, Inc. | Chief Executive Officer | - |
Juno Pharmaceuticals Corp.
 Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | Director/Board Member | - |
Anciens postes connus de Ian Jacobson
| Sociétés | Poste | Fin |
|---|---|---|
| LITHA HEALTHCARE GROUP LIMITED | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| Cpoint Capital, Inc. | |
Juno Pharmaceuticals Corp.
Juno Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022. | Health Technology |
Litha Healthcare Group Ltd.
 Litha Healthcare Group Ltd. BiotechnologyHealth Technology Litha Healthcare Group Ltd. develops pharmaceutical products and medical devices. The firm distributes products in three main sectors of the South African healthcare industry. It operates through following divisions; Litha Pharma, Medical and Biotech. The company was founded by Selwyn Kahanovitz in 1992 and is headquartered in Johannesburg, South Africa. | Health Technology |
